Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
Astera Labs, Inc. entered into a Transaction Agreement with Amazon.com, Inc. and issued a Warrant to Amazon.com NV Investment Holdings LLC for up to 3,262,299 shares of common stock at an exercise price of $142.82 per share. The Warrant runs through February 5, 2033 and allows cashless exercise.
Shares under the Warrant vest based on performance conditions tied to specified payment tranches of up to $6.5 billion for Astera Labs’ smart fabric switch, signal conditioning, and optical engine products purchased by Amazon and its affiliates. The deal includes customary anti-dilution adjustments, registration rights, and transfer restrictions, and was structured as an unregistered private offering under Section 4(a)(2) of the Securities Act.
Astera Labs, Inc. reported that Chief Accounting Officer and VP, Finance Cota Germaine received two equity awards on February 2, 2026. The awards total 24,933 restricted stock units (RSUs), each RSU representing one share of common stock.
One grant covers 21,817 RSUs that vest 25% on February 15, 2027, with the remaining 75% vesting in 12 equal quarterly installments afterward, contingent on continued service. A second grant of 3,116 RSUs vests 100% on February 15, 2027, also subject to ongoing service. Following these grants, Germaine directly holds 24,989 shares of common stock.
Astera Labs, Inc. insider ownership update: Officer Cota Germaine, who serves as Chief Accounting Officer and Vice President, Finance, filed an initial ownership report. As of January 20, 2026, Germaine beneficially owns 56 shares of Astera Labs common stock, held directly. This filing is a standard Form 3, establishing baseline insider ownership for this executive.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in Astera Labs Inc. common stock. As of 12/31/2025, BlackRock reports beneficial ownership of 10,507,515 shares, representing 6.2% of Astera Labs’ outstanding common stock. BlackRock has sole voting power over 9,904,532 shares and sole dispositive power over 10,507,515 shares, with no shared voting or dispositive power.
The filing states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Astera Labs. Various underlying clients and accounts have rights to dividends and sale proceeds, but no single client has more than five percent of the company’s total outstanding common shares.
Astera Labs, Inc. appointed Germaine Cota, age 45, as Chief Accounting Officer and Vice President of Finance, effective January 20, 2026. She will serve as the company’s principal accounting officer for SEC reporting purposes.
Cota brings extensive finance and accounting experience, having most recently served as Senior Vice President, Finance & Accounting and principal accounting officer at BILL Holdings, Inc., with prior senior roles at 8x8, Inc., Mercari, Inc., and LinkedIn, plus nearly 10 years at Ernst & Young. She holds a B.S. in Accounting from Santa Clara University and is a California CPA.
Her employment terms include a $375,000 annual base salary, a target annual performance bonus equal to 50% of base salary, and a one-time hiring or relocation bonus of $130,000, subject to repayment if employment ends for specified reasons within a year. She is also granted restricted stock units with opportunities to receive $3,500,000 in common stock under a long-term award and $500,000 under a supplemental award, vesting over four years and one year, respectively, contingent on continued employment.
Astera Labs, Inc.'s director and President & COO reported gifting common stock held through an estate-planning trust. On 12/01/2025 and 12/02/2025, a trust labeled “Trust 1” made two bona fide gifts of 71,000 shares each of Astera Labs common stock, reported at a price of $0 per share using transaction code G for gifts.
Following these transactions, the reporting person is shown as indirectly holding 5,864,213 shares through Trust 1, 695,000 shares through “Trust 2,” and 695,000 shares through “Trust 3,” along with 1,599,750 shares held directly. The trusts are described as estate planning vehicles, and the reporting person disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest.
Astera Labs, Inc. (ALAB) reported an insider stock sale by a director on a Form 4. On 11/20/2025, the reporting person sold a total of 2,500 shares of common stock in a series of market transactions at weighted average prices ranging from about $142.09 to $159.11 per share. The filing states these sales occurred automatically under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025, which is designed to allow systematic selling regardless of day-to-day market conditions. After these transactions, the director directly owned 94,851 shares of Astera Labs common stock. No derivative security transactions were reported.
Astera Labs, Inc. (ALAB) reported insider activity by its General Counsel and Secretary via a Form 4. On 11/17/2025, the officer sold several small blocks of common stock to cover tax withholding tied to the vesting and settlement of previously granted restricted stock units. The filing shows sales of 454, 1,051, 1,801 and 1,314 shares at weighted average prices of $146.4164, $145.6894, $144.5341 and $143.5145, respectively, executed through multiple transactions within specified price ranges. After these sales, the reporting person beneficially owned 147,040 shares of Astera Labs common stock in direct ownership. The filing notes that the sales were automatic "sell to cover" transactions mandated by the issuer and do not represent discretionary trades by the insider.
Astera Labs, Inc. (ALAB) reported insider share activity by its Chief Financial Officer on a Form 4. On 11/17/2025, the CFO had several small sales of common stock, including 1,124, 2,609, 4,459 and 3,238 shares, at weighted average prices between $147.0000 and $143.1850 per share. According to the footnotes, these transactions were automatic “sell-to-cover” sales required to satisfy tax withholding tied to the vesting of previously granted restricted stock units, and are described as non-discretionary.
After these sales, the CFO directly beneficially owned 192,297 shares of common stock. In addition, 450,281 shares were held indirectly through the Tate 1997 Living Trust, where the reporting person is a trustee and disclaims full beneficial ownership except for any pecuniary interest.
Astera Labs, Inc. (ALAB) reported insider transactions by its President and COO, who is also a director, on 11/17/2025. The filing shows several same‑day open‑market sales of Common Stock coded as "S", including 4,421 shares at a weighted average price of $146.6536, 21,100 shares at $145.8837, 26,381 shares at $144.8026, 32,385 shares at $143.8385, and 6,172 shares at $143.2526. The footnotes explain these sales were automatic "sell to cover" transactions to satisfy tax withholding obligations upon vesting and settlement of previously granted restricted stock units, and are described as non‑discretionary. After these transactions, the executive is shown as directly holding 1,599,750 Common Stock shares. The report also lists 6,006,213 shares held by "Trust 1", and 695,000 shares each in "Trust 2" and "Trust 3", with the executive disclaiming beneficial ownership except for any pecuniary interest.